For comments, suggestions
Created with Raphaël 2.1.0 05.01.2018 Filing date 18.10.2019 Validation fee payment 31.03.2020 (A1) Patent application published 21.05.2021 AGEPI application filing date 31.07.2021 (T2) Translation of the validated European patent 10.06.2025 05.01.2026 Valid until 06.01.2027 Renewal fee to be paid until 05.01.2038 Patent will expire on

Patent in force


(210)Number of the EPO application18709132
(220)Filing date of the EPO application2018.01.05
(80)EPO patent specification publication (B)EPB nr. 08/2021, 2021.02.24
(110)EPO patent number3601533
(11)Number of the documentMD 3601533 T2
(21)Number of the applicatione 2020 0116
(71)Name(s) of applicant(s), code of the countryIovance Biotherapeutics, Inc., US;
(72)Name(s) of inventor(s), code of the countryWARDELL Seth, US;
BENDER James, US;
LOTZE Michael T., US;
(73)Name(s) of owner(s), code of the countryIOVANCE Biotherapeutics Inc., US;
(54)Title of the inventionProcesses for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
(13)Kind-of-document code T2
(51)International Patent Classification C12N 5/0783 (2010.01.01); C12M 1/04 (2006.01.01)
(19)CountryUS
(41)Date of publication of the application2020.03.31
(49)Date of publication of the translation of the validated European patent specification2021.07.31
(30)Priority201762478506 P, 2017.03.29, US; 201762539410 P, 2017.07.31, US; 201762548306 P, 2017.08.21, US; 201762554538 P, 2017.09.05, US; 201762559374 P, 2017.09.15, US; 201762567121 P, 2017.10.02, US; 201762577655 P, 2017.10.26, US; 201762582874 P, 2017.11.07, US; 201762596374 P, 2017.12.08, US
(74)Patent attorney(Procedură) FOCŞA Valentin, bd. Renaşterii Naţionale, No. 6, of. 08, MD-2024, mun. Chişinău, Republica Moldova
(86)International applicationPCT/US2018/012633, 2018.01.05
(87)International publicationWO 2018/182817, 2018.10.04
Up
/Inventions/details/3601533